Page 77 - MemoriaCIBER-2017ESP

Hepa-C Base de Datos de pacientes con Hepatitis C Crónica
Coordinador: Xavier Forns Bernhardt
Durante el año 2017 el registro multicéntrico Hepa-C de pacientes con hepatitis C tratados en España ha presentado como principal hito la publicación de 9 artículos originales con un factor de impacto acu- mulado de 66,309, que se enumeran a continuación:
1 Alonso S, Riveiro-Barciela M, Fernández I, Rincón D, Real Y, Llerena S, Gea F et al “E ec- tiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis Results of a multicenter real-life cohort ” Journal of Viral Hepatitis 2017;24(4):304-311
Factor de impacto: 4,179
2 Fernández-Carrillo J, Crespo G, De la Revilla J, Castells L, Buti M, Montero JL, Fábrega E et al “Successful Continuation of HCV Treatment Following Liver Transplantation ” Trans- plantation 2017;101(5):1009-1012
Factor de impacto: 3,69
3 Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S et al E ec- tiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ±ribavirin: an early Ac- cess programme for Spanish patients with genotype 1/4 Chronic hepatitis C virus infection J Viral Hepat 2017 Mar;24(3):226-237
Factor de Impacto: 4,179
4 Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I et al “Treatment of Hepatitis C Virus Infection in Patients With Cirrhosis and Predictive Value of Model for End-Stage Liver Disease: Analysis of Data From the Hepa-C Registry ” Hepatology 2017;65(6):1810-1822
Factor de impacto: 11,711
5 Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F et al “E ective- ness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort ” Journal of Hepatology 2017;66(6):1138-1148
Factor de impacto: 10,59
6 Crespo J, Calleja JL, Fernández I, Sacristrán B, Ruiz-Antorán B, Ampuero J, Hernán- dez-Conde M et al “Real-World e ectiveness and safety of oral combination antiviral the- rapy for hepatitis C virus genotype 4 infection ” Clinical Gastroenterology and Hepatology 2017;15(6):945-949
Factor de impacto: 7,68
7 Fernández I, Muñoz-Gómez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, Arias A et al “E cacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C ” Journal of Hepatology 2017;66(4):718-723
Factor de impacto: 10,59
8 Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M et al “High e cacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4” Liver Int 2017;37(12):1823-1832
Factor de impacto: 4,12